Apogee Therapeutics, Inc.
APGE
Classifica tra le azioni
#2351
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its... Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
Prezzo delle azioni
$135.07
Ultima sincronizzazione: 2026-09-04
Capitalizzazione di mercato
$8.36B
Variazione (1 giorno)
0.00%
Variazione (1 anno)
137.21%
Paese
US
Scambia Apogee Therapeutics, Inc. (APGE)
Categoria
Healthcare
Storico del rendimento da dividendi per Apogee Therapeutics, Inc. (APGE)
Il rendimento da dividendi (TTM) di Apogee Therapeutics, Inc. (simbolo azionario: APGE) al 2023-12-31 è: 0.00%
Rendimento medio negli ultimi 5 anni: 0.00%
Rendimento medio negli ultimi 5 anni: 0.00%
Storico del rendimento da dividendi per Apogee Therapeutics, Inc. (APGE) da 2022 a 2026
Rendimento da dividendi alla fine di ogni anno (TTM)
| Anno | Rendimento da dividendi | Cambia |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
Rendimenti da dividendi (TTM) di aziende simili o concorrenti
| Azienda | Rendimento da dividendi | Il paese |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.17% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
